Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 186 for:    GLYCOPYRROLATE

The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03081156
Recruitment Status : Completed
First Posted : March 16, 2017
Last Update Posted : February 4, 2019
Sponsor:
Information provided by (Responsible Party):
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Brief Summary:
This trial is an investigator initiated study involving the use of the AstraZenica Aerophere Inhaler (Glycopyrrolate/Formoterol) to determine the effect on exercise tolerance and dynamic hyperinflation in patients with chronic obstructive lung disease.

Condition or disease Intervention/treatment Phase
Pulmonary Disease, Chronic Obstructive Drug: Glycopyrrolate / Formoterol Phase 4

Detailed Description:

Patients with chronic obstructive pulmonary disease (COPD) have obstruction to expiratory airflow, marked breathlessness, high dyspnea scores, and reduced exercise tolerance relative to age and gender matched non-smoking controls (Casaburi, 2009; Casaburi et al., 2014; Puente-Maestu et al., 2016). A prominent mechanism for exercise intolerance is thought to be dynamic hyperinflation during exercise (an increase in the end-expiratory lung volume) that contributes to the sensation of breathlessness, and ultimately results in early cessation of exercise. A co-maladaptive mechanism of exercise limitation in COPD is related to wasted or excessive ventilation at all work intensities from increased dead space ventilation relative to total ventilation (increased VD/VT). This requirement for additional ventilation limits exercise capacity and contributes to dynamic hyperinflation and ventilatory limitation (O'Donnell et al., 2004).

Treatment with individual bronchodilators, including short acting beta agonists (SABA), long acting beta agonists (LABA), short acting muscarinic antagonists (SAMA) and long acting muscarinic antagonists (LAMA) is effective in partially reversing the expiratory airflow obstruction at rest and during exercise resulting in reduced dynamic hyperinflation. Because beta-agonists and anticholinergics broncho-dilate synergistically, they are often used in combination products (SABA+SAMA or LABA/LAMA). The optimal sustained bronchodilation effect in COPD appears to be achieved by fixed dose, long acting combination medications (LABA/LAMA). (Bateman et al., 2014; Casaburi, 2009; Casaburi et al., 2014; Cope et al., 2013; Huisman et al., 2015). As dynamic hyperinflation appears to also be a limiting factor in exercise tolerance, and LABA/LAMA preparations improve airflow during exercise, it appears likely that use of a fixed-dose combination bronchodilator, BEVESPI AEROSPHERE ® (Glycopyrrolate/Formoterol) will increase exercise tolerance and reduce hyperinflation in COPD patients.

We hypothesize that exercise tolerance in a constant work rate, high intensity cardiopulmonary exercise test will be increased with BEVESPI AEROSPHERE ® (Glycopyrrolate/Formoterol), and that the increase in exercise tolerance will be mediated by a combination of:

  1. reduced dynamic hyperinflation, and
  2. decreased dead space ventilation (VD/VT) during exercise.

Primary objective:

To determine the magnitude of exercise time improvement (seconds) with BEVESPI AEROSPHERE ® (Glycopyrrolate/Formoterol) relative to placebo during high intensity, constant work rate exercise in COPD patients.

Secondary objective:

To determine if the VD/VT can be reliably assessed during constant work rate exercise using transcutaneous CO2 measurement (tcpCO2) and, if so, if BEVESPI AEROSPHERE ® (Glycopyrrolate/Formoterol) results in a reduction in VD/VT relative to placebo at isotime during high intensity constant work rate exercise in COPD patients.

Tertiary objective:

To determine if computerized assessment of the spontaneous expiratory flow-volume loop during exercise can provide additional information about both dynamic hyperinflation and the effects of BEVESPI AEROSPHERE ® (Glycopyrrolate/Formoterol) during high intensity, constant work rate exercise in COPD patients.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: An Investigator Initiated, Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of Glycopyrrolate/Formoterol on Exercise Tolerance and Dynamic Hyperinflation in Patients With Chronic Obstructive Pulmonary Disease.
Actual Study Start Date : March 27, 2017
Actual Primary Completion Date : January 1, 2019
Actual Study Completion Date : January 31, 2019


Arm Intervention/treatment
Active Comparator: Glycopyrrolate/Formoterol Inhaler
Treatment for 2 weeks with Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
Drug: Glycopyrrolate / Formoterol
Exercise Tolerance
Other Name: Bevespi Aerosphere

Placebo Comparator: Placebo
Treatment for 2 weeks with a placebo Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
Drug: Glycopyrrolate / Formoterol
Exercise Tolerance
Other Name: Bevespi Aerosphere




Primary Outcome Measures :
  1. Magnitude of exercise time improvement (seconds) during cycle ergometer execise. [ Time Frame: 52 weeks ]
    To determine the magnitude of exercise time improvement (seconds) with BEVESPI AEROSPHERE ® (Glycopyrrolate/Formeterol) relative to placebo during high intensity, constant work rate cycle ergometer exercise in COPD patients.


Secondary Outcome Measures :
  1. VD/VT as determined by transcutaneous CO2 measurement (tcpCO2) during constant work rate cycle ergometer exercise. [ Time Frame: 52 weeks ]
    To determine if the VD/VT can be reliably assessed during constant work rate exercise using transcutaneous CO2 measurement (tcpCO2) and, if so, if BEVESPI AEROSPHERE ® (Glycopyrrolate/Formeterol) results in a reduction in VD/VT relative to placebo at isotime during high intensity constant work rate exercise in COPD patients.


Other Outcome Measures:
  1. Computerized analysis of the spontaneous expiratory flow-volume loop during exercise [ Time Frame: 523 weeks ]
    To determine if computerized assessment of the spontaneous expiratory flow-volume loop during exercise can provide additional information about both dynamic hyperinflation and the effects of BEVESPI AEROSPHERE ® (Glycopyrrolate/Formeterol) during high intensity, constant work rate exercise in COPD patients.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. All patients must have a clinical diagnosis of chronic obstructive pulmonary disease (COPD) and must meet the following criteria:

    1. Stable state of their disease with no exacerbation (antibiotics, oral steroids, ER visit, or hospitalization for COPD) within the previous 4 weeks; and
    2. At visit 1 Spirometric Values must demonstrate a post-bronchodilator FEV1 between 35% and 80% of predicted normal and a post-bronchodilator FEV1/FVC <70%. [The rationale for the lower limit is to exclude patients unlikely to tolerate withholding of long acting bronchodilators. The rationale for the upper limit is to exclude patients unlikely to be limited in their exercise tolerance by hyperinflation and air trapping.]
  2. Male or female patients, between 40 and 80 years (inclusive) of age.
  3. Patients must be current or ex-smokers with a smoking history of more than 10 pack-years.
  4. Patients must be able to perform technically acceptable pulmonary function tests and a symptom-limited cardiopulmonary cycle ergometry test.
  5. Patients must be able to inhale medication in an acceptable manner from the metered dose inhalers used in this study.

Exclusion Criteria:

  1. Patients with a significant disease other than COPD; a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patient's ability to participate in the study.
  2. Patients with a documented personal history of childhood asthma, a clinical presentation consistent with asthma, and a family history of asthma. For patients with allergic rhinitis, atopy, or prior allergy treatment, medical records will be obtained to verify that the patient does not have asthma. The final determination on the possibility of an overlap condition [Asthma-COPD Overlap Syndrome, (Postma and Rabe, 2015)], and thus, appropriateness for entry into the study, will be the principal investigator's decision.
  3. Patients with any of the following conditions:

    1. A history of myocardial infarction within 1 year of screening visit.
    2. Unstable or life-threatening cardiac arrhythmia.
    3. Hospitalized for heart failure within the past year.
    4. Known active tuberculosis.
    5. A malignancy for which patient has undergone resection, radiation therapy or chemotherapy within the past 6 months (patients with treated local skin tumors are allowed).
    6. A history of life-threatening COPD exacerbation requiring intubation.
    7. A history of cystic fibrosis.
    8. Clinically significant and active bronchiectasis.
    9. A history of alcohol or drug abuse within the past year.
    10. Any contraindications for exercise testing as outlined below (see contraindications to exercise).
    11. Patients who have undergone thoracotomy with pulmonary resection in the past year.
  4. Patients being treated with oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day.
  5. Patients who regularly use daytime oxygen therapy for more than 6 hours per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy during clinic visits and exercise testing.
  6. Patients who desaturate to SpO2 <80% on screening incremental exercise testing.
  7. Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit or patients who are currently in a pulmonary rehabilitation program.
  8. Patients who have a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnea, such as arthritis in the leg, angina pectoris or claudication or morbid obesity.
  9. Patients with a constant power cycle ergometry endurance time less than 4 or greater than 8 minutes after work rate adjustment procedures (described below).
  10. Patients who have taken an investigational drug within one month or six half-lives (whichever is greater) prior to screening visit (Visit 1).
  11. Pregnant or nursing women.
  12. Women of childbearing potential who are not using a highly effective method of birth control. Female patients will be considered to be of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation, or post-menopausal for at least two years.
  13. Patients who are currently participating in another interventional study.
  14. Patients who are unable to comply with pulmonary medication restrictions (washout of any LABA/LAMA) prior to randomization.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03081156


Locations
Layout table for location information
United States, California
Los Angeles Biomedical Institute, Inc (LABIOMED)
Torrance, California, United States, 90509
Sponsors and Collaborators
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Layout table for additonal information
Responsible Party: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
ClinicalTrials.gov Identifier: NCT03081156     History of Changes
Other Study ID Numbers: 21752-01
First Posted: March 16, 2017    Key Record Dates
Last Update Posted: February 4, 2019
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center:
chronic obstructive pulmonary disease (COPD)
exercise intolerance
dynamic hyperinflation
Additional relevant MeSH terms:
Layout table for MeSH terms
Glycopyrrolate
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Lung Diseases, Obstructive
Formoterol Fumarate
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adjuvants, Anesthesia
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents